– Orotates
And The
Mineral Transporters
Of Dr. Nieper –
by
Ed Sharpe
What’s the best
way to take mineral supplements? Picolinates? Amino acid chelates?
Chelates involving other organic acids such as citrates? Whenever
anyone asks my opinion on such matters, I find myself giving
an answer they often don’t expect: “Try orotates!” The
blank looks I usually get in response tell me that most people
need some educating on the subject, hence this article.
Orotates are the mineral
salts of orotic acid, a natural substance found in our bodies
and also in various foods including dairy products. As theorized
many years ago by the pioneering German physician Hans Nieper,
orotates are a component of a natural system of electrolyte
carriers for distributing minerals throughout the body. 1 (A
different compartment of this same system uses amino acid complexes
such as aspartates and arginates to deliver minerals.) Based
on his observations of cells in culture, Nieper concluded that
molecules of calcium orotate and magnesium orotate can pass
through cell membranes intact without “dissociating” or
breaking apart into their component ions, and thereafter release
their respective ions only at specific membrane sites within
the cell. 2 Subsequently he extended
this principle to include other orotates such as lithium and
zinc.
Working at his clinic
in Hannover, Germany, Nieper applied his unique discoveries
to the treatment of diseases such as cancer, heart disease,
multiple sclerosis, and rheumatoid arthritis as well as other
autoimmune conditions. Over the course of more than four decades
Dr. Nieper treated thousands of patients with his innovative
mineral transporters, many apparently with great success. However,
in later years he published relatively little in medical journals,
preferring instead to reserve his time for treating patients
and for presenting occasional seminars about his work to medical
professionals and consumers. As a result, his discoveries have
been considered controversial by mainstream medicine or simply
ignored, at least until recently.
Hans Nieper died in
October, 1998 at the age of 70—ironically just at a time
when many of his ideas had finally begun gaining wider acceptance.
Only a few weeks before his death, in fact, the collected papers
from a symposium on the medical uses of magnesium orotate were
published in the journal Cardiovascular Drugs and Therapy.
Overall, the symposium lent credence to Nieper’s claims
for the cardiovascular benefits of magnesium orotate while
calling for additional human trials. 3
How do the orotates work?
That’s a complex
question necessitating a somewhat detailed discussion of biochemistry
and for this reason my explanation has been relegated to an
article of its own. See How Orotates Work. For now I’ll
just state my summary conclusions: There is independent scientific
evidence corroborating Nieper’s theory of orotates as
mineral transporters. In my judgment, the evidence tends to
support Nieper’s criteria for orotate as an electrolyte
carrier, namely, (1) a low dissociation constant, (2) an affinity
for specific cellular systems or organs, and (3) a metabolic
pathway which liberates the transported mineral within the
targeted organ or system. 1
Perhaps the recent
wave of interest in Dr. Nieper’s compounds will inspire
further research on the mechanism of transport. Until then
there’s plenty of evidence for the validity of Dr. Nieper’s
ideas in previous publications by Nieper and other researchers.
The following sections summarize these results on the medical
and biological effects of the various mineral orotates, together
with a brief discussion of other potential uses. Beyond that,
there is direct and compelling evidence from personal experience—see
my article Orotates for Weight Loss, Cognitive Enhancement,
and Athletic Performance for details. To give but one example,
there can be little doubt about the effectiveness of Nieper’s
products when the majority of people trying calcium orotate
as an appetite suppressant can tell almost immediately that
it works, just as Nieper said it would.
Magnesium orotate
Of all the macronutrient
minerals in the human body, magnesium is the one most likely
to be deficient. Magnesium deficiency has been linked to a
large number of disorders, including diabetes 4,
hypertension 5, dementia 6,
and osteoporosis. 7 Magnesium
compounds are medically accepted as helpful for treating migraines,
asthma, chronic lung disease, and cardiac conditions such as
heart attack and arrhythmias. 8 Magnesium
orotate should be even more effective than other magnesium
supplements for such conditions, in view of its enhancement
of magnesium transport and its documented benefits 3, 9, 10 in
cardiovascular disorders.
In addition to its
cholesterol-lowering and heart-energizing effects, magnesium
orotate has also been reported to improve the elasticity of
blood vessels. 11 Using capillarographic
recordings Dr. Nieper was able to show that a daily dose of
380 mg magnesium orotate over 15 months was sufficient to normalize
or greatly improve the elasticity of peripheral blood vessels
in 60 of 64 patients. Such an effect on vessel elasticity suggests
the use of magnesium orotate for lowering blood pressure as
well as for inhibiting arteriosclerosis.
Dr. Nieper generally
combined magnesium orotate with other nutrients for optimal
effect. For example, it’s known that potassium deficiency
is closely linked with magnesium deficiency because magnesium
ions are needed to activate an important cellular pump which
regulates sodium and potassium levels. 4, 5 In
addition, potassium orotate itself is thought to be beneficial
for conditions such as cardiomyopathy and congestive heart
failure (see section below on Potassium orotate). So it’s
not surprising to find that Nieper recommended a combination
of magnesium orotate (1.5 to 2.5 grams per day) plus potassium
orotate (138 to 300 mg daily) for treating angina and coronary
heart disease. 12 He also suggested
adding the pineapple enzyme bromelain (120 to 140 mg per day)
to inhibit platelet aggregation and dissolve fibrin clots.
The 2- and 4-year mortality rates for patients on this regimen
were reportedly reduced by 90% or more compared to patients
in other studies who received conventional medications. 12
A similar Nieper combination
designed for unclogging arteries involved magnesium orotate
(1 to 1.5 grams per day) together with carnitine (4 grams per
day), selenium (Se-enriched yeast, 300 to 400 mcg per day),
bromelain (240 mg daily), and the enzyme serrapeptase 10 to
15 mg per day). See my article on CardioPeptase for additional
information.
Finally, it’s
worth pointing out that magnesium orotate isn’t just
for heart patients—it’s also for healthy athletes.
In a double-blind, randomized study, 23 competitive triathletes
were studied after 4 weeks of supplementation with placebo
or magnesium orotate. 13 Blood
was collected before and after a test consisting of a 380-meter
swim, a 20-km bicycle race, and a 5-km run. Compared to placebo,
magnesium orotate caused a greater increase during the test
in serum glucose and venous partial pressure of oxygen, and
a greater decrease in serum insulin, blood acidity, and serum
cortisol. The changes in glucose use and reduction in stress
responses occurred without affecting the athletes’ competitive
potential-quite the reverse, in fact. The exercising athletes
had greater endurance as a result of the magnesium orotate
supplements. By contrast, a different study in which athletes
were supplemented with magnesium oxide (which is relatively
poorly absorbed) reported no improvement in exercise performance,
attesting to the superior uptake of magnesium in the orotate
form compared to the oxide. 14
Potassium orotate
Potassium deficiency
is not considered to be common in view of the availability
of adequate amounts of this mineral in most diets. Nevertheless,
potassium deficiency is known to arise as a secondary consequence
of magnesium deficiency. 5 Another
cause of deficiency is the use of potassium-wasting diuretics
to control high blood pressure. 15 Disease
states known to be associated with low serum or tissue potassium
include diabetes 4, insulin resistance 16,
and high blood pressure 5, 17 as
well as rheumatoid arthritis18 and heart disease. 18
Dr. Nieper’s
original motivation to develop orotic acid as an electrolyte
carrier was inspired by results due to E. Bajusz showing that
potassium orotate can prevent idiopathic myocardial necrosis
in hamsters, while potassium chloride is ineffective. 19, 20 Nieper
subsequently found that potassium orotate was highly effective
for alleviating human cardiovascular diseases when combined
with magnesium orotate (see discussion in the section below
on Magnesium orotate). Even when administered by itself to
heart attack patients, potassium orotate has been reported
to result in faster recovery of myocardial contractibility
than in placebo-treated controls. 21
Other reported applications
for potassium orotate include acceleration of wound healing 22 and
enhancement of recovery and immune function following surgery. 23 Although
not an antioxidant itself, potassium orotate facilitates the
tissue uptake of vitamin C from serum and increases blood levels
of reduced glutathione. 24 Finally,
studies in animals have revealed antidepressant, psychostimulant,
and anxiety-reducing effects associated with chronic potassium
orotate administration. 25, 26
Lithium orotate
Although no absolute
need for lithium has yet been established in human nutrition,
lithium intake can affect many different systems in the body
in a positive way. Lithium is most famous for treatment of
manic-depressive disorders. At high doses lithium can depress
dopamine release 27 (which
tends to flatten elevated moods), while at lower doses it can
stimulate serotonin synthesis 28 (which
gives an antidepressant effect). Although most people don’t
need treatment for manic-depressive illness, a very large number
with mild depression could benefit from low-dose lithium supplements.
Recently it’s been discovered that lithium has potent
neuroprotective effects as well (see the article Lithium increases
gray matter in the brain). The hope now is that lithium supplements
will prove capable of halting the progress of neurodegenerative
diseases such as Alzheimer’s, Parkinson’s, and
amyotrophic lateral sclerosis, among others.
Lithium is also known
for its immune-enhancing and antiviral effects, especially
against herpes simplex virus. 29 It
may be equally effective against measles, judging by results
obtained in vitro. 30 The
downside to lithium’s immune-stimulating activity is
that it can also set off autoimmune reactions in susceptible
individuals. 31 For
this reason, if you suffer from an existing autoimmune disease
such as rheumatoid arthritis or lupus, don’t take lithium
supplements without first consulting your health care professional.
Another benefit of
supplementing with lithium is its insulin-sensitizing effect. 32 Lithium
has been found to decrease blood glucose levels, especially
when used in conjunction with insulin or oral glucose-lowering
drugs. 33 Results
such as these have led to suggestions that lithium might be
useful in treating diabetes. 32, 33
As expected in view
of the neurological activity of lithium compounds, Dr. Nieper
found that lithium orotate in doses of 138 mg 4 to 6 times
per week was effective in treating cases of depression, headaches
and migraine, epilepsy, and even alcoholism. 34 The
amount of lithium contained in the doses was only a small fraction
of the amount conventionally given as therapy for manic-depressive
illness, thus avoiding the risk of kidney toxicity typically
associated with high-dose lithium. Elsewhere Dr. Nieper reported
that 5 mg of lithium in the form of orotate was roughly as
effective as 100 mg of lithium in the form of carbonate, giving
a 20-fold enhancement of potency thanks to efficient transport
of the lithium by its orotate carrier. 35
Nieper’s results
were subsequently confirmed in a group of 42 alcoholic patients
who were followed for between 6 months and 10 years. 36 Treatment
with 138 mg of lithium orotate per day resulted not only in
a marked decline in alcoholic relapses, but also in improvements
in liver, cardiovascular, thyroid, and immune function. Migraines,
cluster headaches, manic behavior, and seizure disorders were
also reduced among this group. Eight patients reportedly developed
muscle weakness, loss of appetite, and mild apathy as a result
of treatment, but symptoms disappeared after the dose was reduced
to 138 mg 4 to 5 times per week. The improvements in liver
function appeared to be due to a synergy between lithium orotate
and calcium orotate, both of which were administered to the
alcoholic patients with liver disease. For more information
on the treatment of liver disorders with a combination of lithium
and calcium orotate, see the section below on Calcium orotate.
Note on lithium safety
As mentioned above,
lithium in large doses can be toxic, especially to the kidneys.
The therapeutic dose of lithium when administered as lithium
carbonate is close to the toxic dose (i.e., there is a narrow
therapeutic window), and for this reason blood levels and organ
function need to be monitored continually. This is true only
for lithium carbonate and not for lithium orotate. For example,
according to the Physicians’ Desk Reference, the recommended
dose of lithium carbonate administered for treatment of psychiatric
disorders is 300 mg three to four times per day. Since each
300 mg tablet of lithium carbonate provides 56.8 mg of elemental
lithium, the total amount of lithium delivered would range
from 170.4 mg to 225.6 mg per day. By contrast one lithium
orotate tablet delivers 5.8 mg elemental lithium, which is
roughly 1/30 to 1/40 the amount delivered by the recommended
daily dose of lithium carbonate. Even taking several lithium
orotate tablets per day would amount to a dose well below the
toxic level for lithium.
Similarly, consumers
of lithium carbonate are often warned of possible toxic effects
if other medications such as ACE inhibitors or diuretics are
taken concurrently. Although these warnings appear to be true
for pharmaceutical lithium compounds only and not for modest
doses of lithium orotate, it would nevertheless be wise to
consult with a health care professional for anyone contemplating
taking lithium orotate concurrently with either of these medications.
Zinc orotate
Zinc deficiency has
been implicated in age-related osteoporosis 37 and,
conversely, zinc supplements can speed the healing of fractures
in animal models. 38 Zinc also
plays a vital role in immune function, where deficiency is
associated with atrophy of the thymus, reduction in white blood
cell counts, and increased susceptibility to infection. 39, 40 Another
important role for zinc is in maintaining male reproductive
function. Deficiency of zinc is associated with hypogonadism
and low levels of serum testosterone, reversible upon supplementation. 41 Zinc
also appears to be important for the activity of growth hormone
(GH) since GH loses effectiveness under conditions of zinc
deficiency. 42
As is well known, one
of the major roles for zinc in human nutrition is its antioxidant
activity. 43 Increasing zinc intake
may protect against conditions associated with both oxidant
stress and zinc deficiency, such as diabetes. 44 Zinc
deficiency is known to be associated with an increased prevalence
of coronary artery disease as well as diabetes, and with several
associated risk factors including hypertension, hypertriglyceridemia,
and insulin resistance (syndrome X). 45, 46
In view of the association
of zinc deficiency with diabetes, it’s not surprising
to learn that zinc orotate stabilizes blood glucose and reduces
the need for insulin in diabetics, according to Dr. Nieper. 35 In
addition, zinc orotate and other zinc compounds synergize with
sulfur-containing antioxidants (sulfhydryls) to protect against
free radical-induced tissue injury 43, 47,
a result which may have relevance to the treatment of diabetes
as well as other diseases of increased oxidative stress. 44
Calcium orotate
Treatment or prevention
of osteoporosis is one of the main applications for calcium
supplements generally and for calcium orotate in particular.
Dr. Nieper specifically cited its effectiveness in treating
both inflammatory and osteoporotic decalcification and in relieving
pain resulting from osteoporosis of the spine. 19 In
another paper Nieper reported successful recalcification of
malignant bone tumors (thereby preventing further metastases)
with calcium orotate in 10 out of 13 subjects. 1 He
also found that a daily oral dose of about 600 mg was sufficient
to reverse bone loss caused by radiological therapy in cancer
patients, an effect documented by X-ray photos of several subjects
before and after treatment with calcium orotate. 1, 19 A
further paper reported on the benefits of calcium orotate in
treating joint diseases such as arthritis and spondylitis. 48 On
the basis of results such as these, it seems likely that calcium
orotate can also have a beneficial impact on the degenerative
bone changes characteristic of osteoarthritis. (For information
on an orotate formulation optimized for bone health, see description
below of Osteo Forte Orotate.)
But calcium orotate
has many other uses as well. In his remarkable paper of 1969
Dr. Nieper reported his observations after dispensing more
than 38,000 doses of calcium orotate to a large number of patients
over the course of a year. 19 Nieper
found that low-dose calcium orotate was effective in treating
severe refractory psoriasis, lowering blood pressure in cases
of arteritis and arteriosclerosis, relieving angina pectoris,
and ameliorating cases of multiple sclerosis, disseminated
encephalitis, retinitis, chronic hepatitis, and colitis. The
dosages employed varied from about 300 to 1000 mg calcium orotate
per day. No side effects were noted except for a loss of appetite
among obese chronic overeaters, some of whom were able to lose
a substantial amount of excess weight.
In subsequent research
Nieper reported achieving complete remissions of chronic, aggressive
hepatitis in 14 patients treated with 3 grams of calcium orotate
per day for 2 years; 4 of these patients also required cortisone
therapy, although at a decreased dosage. 49 Nieper
found that an optimal therapeutic effect was achieved after
a period of 9 to 18 months of daily supplementation, but not
earlier. However, with a regimen of 2 grams calcium orotate
plus 138 mg lithium orotate per day, the same beneficial results
could be achieved in cases of hepatitis and cirrhosis in only
2 to 3 months. This research should be re-investigated in view
of the emerging global health crisis of hepatitis C.
Around 1975 Dr. Nieper
began treating lupus erythematosus patients with calcium orotate.
35 He found that a dose of 1 to 2.5 grams was surprisingly
effective when administered over a period of at least one year,
even in advanced cases with pulmonary constriction, pleural
effusions, or cardiomyopathy. 35, 50 Therapy
also involved low-dose prednisone and a variety of nutrients
to promote adrenal steroid synthesis, such as selenium and
vitamins C and D2, as well as other calcium and magnesium salts.
An account of one patient’s successful response to therapy
with calcium orotate and other Nieper compounds can be found
in an article available from the Brewer Science Library. 51 In
addition Nieper found that multiple sclerosis sometimes accompanies
lupus, so it’s not surprising that his protocol for treating
MS is strikingly similar to that for treating lupus. 52, 53 He
recommended a dose of 1 gram calcium orotate per day for MS
patients, with a higher dose given to those patients with a
tendency toward migraine-like headaches.
Osteo Forte orotate
The benefits of calcium
orotate for healthy bone metabolism can be amplified by adding
a variety of other minerals. Magnesium 7,
manganese 54, zinc 36,
and boron 55 are all known to
act in concert with vitamin D and calcium. Osteo Forte Orotate
combines calcium, zinc, and magnesium orotates with other nutrients
in a synergistic formulation optimal for maintaining bone health.
References
-
Nieper HA. Recalcification
of bone metastases by calcium diorotate. Agressologie.
1970;11(6):495-502. Available as article #CA21 from the
A. Keith Brewer International Science Library at (608)
647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Nieper HA. The
clinical applications of lithium orotate. A two years study.
Agressologie. 1973;14(6):407-11. Available as article #CM12
from the A. Keith Brewer International Science Library
at (608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Rosenfeldt FL.
Metabolic supplementation with orotic acid and magnesium
orotate. Cardiovasc Drugs Ther. 1998;12(Suppl 2):147-52.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Durlach J, Collery
P. Magnesium and potassium in diabetes and carbohydrate
metabolism. Review of the present status and recent results.
Magnesium. 1984;3(4-6):315-323. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Altura BM, Altura
BT. Interactions of Mg and K on blood vessels—aspects
in view of hypertension. Review of present status and new
findings. Magnesium. 1984;3(4-6):175-94.
-
Glick JL. Dementias:
the role of magnesium deficiency and an hypothesis concerning
the pathogenesis of Alzheimer's disease. Med Hypotheses.
1990;31:211-225. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Rude RK, Kirchen
ME, Gruber HE, Meyer MH, Luck JS, Crawford DL. Magnesium
deficiency-induced osteoporosis in the rat: uncoupling
of bone formation and bone resorption. Magnes Res. 1999;12(4):257-67.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Swain R, Kaplan-Machlis
B. Magnesium for the next millennium. South Med J. 1999;92(11):1040-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Villanyi P, Votin
J, Rahlfs V. Arteriosclerosis, myocardial infarct and blood
lipids, their therapeutic modification by magnesium orotate
[in German]. Wien Med Wochenschr. 1970;120(5):76-83.
-
Jellinek H, Takacs
E. Morphological aspects of the effects of orotic acid
and magnesium orotate on hypercholesterolaemia in rabbits.
Arzneimittelforschung. 1995;45(8):836-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Nieper HA. Capillarographic
criteria on the effect of magnesium orotate, EPL substances
and clofibrate on the elasticity of blood vessels. Agressologie.
1974;15(1):73-7. Available as article #CM19 from the A.
Keith Brewer International Science Library at (608) 647-6513
or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Nieper HA. Lowering
of incidence of infarction by means of magnesium orotate
and potassium orotate in combination with bromelain [in
German; unpublished ms., 1977]. Cited in: Heart disease
treated with orotates and bromelain. Available as article
#CM17 from the A. Keith Brewer International Science Library
at (608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Golf SW, Bender
S, Gruttner J. On the significance of magnesium in extreme
physical stress. Cardiovasc Drugs Ther. 1998;12(Suppl 2):197-202.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Weller E, Bachert
P, Meinck HM, Friedmann B, Bartsch P, Mairbaurl H. Lack
of effect of oral Mg-supplementation on Mg in serum, blood
cells, and calf muscle. Med Sci Sports Exerc. 1998;30(11):1584-91.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Franse LV, Pahor
M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia
associated with diuretic use and cardiovascular events
in the Systolic Hypertension in the Elderly Program. Hypertension.
2000;35(5):1025-30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
[Full text] [PDF (110 KB)]
-
Norbiato G, Bevilacqua
M, Meroni R, et al. Effects of potassium supplementation
on insulin binding and insulin action in human obesity:
protein-modified fast and refeeding. Eur J Clin Invest.
1984;14(6):414-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Rubenowitz E,
Landin K, Wilhelmsen L. Skeletal muscle magnesium and potassium
by gender and hypertensive status. Scand J Clin Lab Invest.
1998;58(1):47-54. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Weber CE. Potassium
in the etiology of rheumatoid arthritis and heart infarction.
J Appl Nutr. 1974;26(1-2):41-67.
-
Nieper HA. The
anti-inflammatory and immune-inhibiting effects of calcium
orotate on bradytrophic tissues. Agressologie. 1969;10(4):349-57.
Available as article #CM14 from the A. Keith Brewer International
Science Library at (608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Bajusz E. Interrelationships
between reparative processes in myocardium and the development
of congestive heart failure. Rev Can Biol. 1968;27(1):45-60.
-
Tomov L, Kaloianova
A. Changes in hemodynamics in acute myocardial infarct
following administration of potassium orotate [in Bulgarian].
Vutr Boles. 1976;15(4):79-82. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Kolokol'chikova
EG, Pal'tsyn AA. Electron-radioautographic study of the
effect of potassium orotate on RNA and protein synthesis
in fibroblasts during experimental wound healing [in Russian].
Biull Eksp Biol Med. 1983;96(8):115-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Bilich GL, Nazarova
LV, Sungurova EV. The enzymatic status of circulating lymphocytes
as an index of the regenerative process in the lungs under
stimulation with pyrimidine and purine derivatives. A clinical
experimental study. Haematologia (Budap). 1982;15(1):71-81.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Kuzdenbaeva RS,
Kurakina VE, Iztleuov MK. Effect of anabolic substances
on the state of the individual components of the glutathione-ascorbic
acid system [in Russian]. Farmakol Toksikol. 1980;43(5):607-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Karkishchenko
NN, Khaitin MI. Comparative study of the indices of the
antidepressive activity of potassium orotate and piracetam
[in Russian]. Farmakol Toksikol. 1985;48(2):32-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Karkishchenko
NN, Khaitin MI. Quantitative evaluation of the anxiolytic
and nootropic effects of potassium orotate in a wide range
of doses [in Russian]. Farmakol Toksikol. 1986;49(1):14-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Dziedzicka-Wasylewska
M, Mackowiak M, Fijat K, Wedzony K. Adaptive changes in
the rat dopaminergic transmission following repeated lithium
administration. J Neural Transm Gen Sect. 1996;103(7):765-76.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Perez-Cruet J,
Tagliamonte A, Tagliamonte P, Gessa GL. Stimulation of
serotonin synthesis by lithium. J Pharmacol Exp Ther. 1971;178(2):325-30.
-
Rybakowski JK.
Antiviral and immunomodulatory effect of lithium. Pharmacopsychiatry.
2000;33(5):159-64. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Cernescu C, Popescu
L, Constantinescu S, Cernescu S. Antiviral effect of lithium
chloride. Virologie. 1988;39(2):93-101. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Lieb J. Lithium
and immune function. Med Hypotheses. 1987;23(1):73-93.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Tabata I, Schluter
J, Gulve EA, Holloszy JO. Lithium increases susceptibility
of muscle glucose transport to stimulation by various agents.
Diabetes. 1994;43(7):903-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Hu M, Wu H, Chao
C. Assisting effects of lithium on hypoglycemic treatment
in patients with diabetes. Biol Trace Elem Res. 1997;60(1-2):131-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Nieper HA. The
clinical applications of lithium orotate. A two years study.
Agressologie. 1973;14(6):407-11. Available as article #CM12
from the A. Keith Brewer International Science Library
at (608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Nieper HA. Revolution
in Technology, Medicine and Society. Oldenburg, Germany:
MIT Verlag; 1985. Available from the A. Keith Brewer International
Science Library at (608) 647-6513 or on the Web.
-
Sartori HE. Lithium
orotate in the treatment of alcoholism and related conditions.
Alcohol. 1986;3(2):97-100. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Atik OS. Zinc
and senile osteoporosis. J Am Geriatr Soc. 1983;31(12):790-1.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Igarashi A, Yamaguchi
M. Increase in bone protein components with healing rat
fractures: enhancement by zinc treatment. Int J Mol Med.
1999;4(6):615-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Mocchegiani E,
Giacconi R, Muzzioli M, Cipriano C. Zinc, infections and
immunosenescence. Mech Ageing Dev. 2000;121(1-3):21-35.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Fraker PJ, Jardieu
P, Cook J. Zinc deficiency and immune function. Arch Dermatol.
1987;123(12):1699-701. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Prasad AS, Mantzoros
CS, Beck FW, Hess JW, Brewer GJ. Zinc status and serum
testosterone levels of healthy adults. Nutrition. 1996;12(5):344-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Kurtogu S, Patiroglu
TE, Karakas SE. Effect of growth hormone on epiphyseal
growth plates in zinc deficiency. Tokai J Exp Clin Med.
1987;12(5-6):325-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Powell SR. The
antioxidant properties of zinc. J Nutr. 2000;130(5S Suppl):1447S-54S.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
[Full text] [PDF (249 KB)]
-
DiSilvestro RA.
Zinc in relation to diabetes and oxidative disease. J Nutr.
2000;130(5S Suppl):1509S-11S. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
[Full text] [PDF (153 KB)]
-
Singh RB, Niaz
MA, Rastogi SS, Bajaj S, Gaoli Z, Shoumin Z. Current zinc
intake and risk of diabetes and coronary artery disease
and factors associated with insulin resistance in rural
and urban populations of North India. J Am Coll Nutr. 1998;17(6):564-70.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Falkiewicz B,
Dabrowska E, Lukasiak J, Cajzer D, Jablonska-Kaszewska
I. Zinc deficiency and normal contents of magnesium and
calcium in metabolic X syndrome patients as assessed by
the analysis of hair element concentrations. Biofactors.
2000;11(1-2):139-41.
-
Floersheim GL.
Synergism of organic zinc salts and sulfhydryl compounds
(thiols) in the protection of mice against acute ethanol
toxicity, and protective effects of various metal salts.
Agents Actions. 1987;21(1-2):217-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Nieper HA. The
clinical effect of calcium-diorotate on cartilage tissue,
the specific function dependent upon the pentose metabolism
of bradytrophic tissue [in German]. Z präkt Geriatrie.
1973;3(4):82-9. English translation available as article
#CM29 from the A. Keith Brewer International Science Library
at (608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Nieper HA. Liver
orotate: the curative effect of a combination of calcium-orotate
and lithium-orotate on primary and secondary chronic (aggressive)
hepatitis and primary and secondary liver cirrhosis (lecture,
1974). Available as article #CM11 from the A. Keith Brewer
International Science Library at (608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Nieper HA. Excerpts
of comments by Dr. Nieper from various sources, p. 12 (workshop
transcript, 1987). In: Doctor's packet regarding MS and
other illnesses. Available from the A. Keith Brewer International
Science Library at (608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Pakkala A, Pakkala
L. The muzzled wolf. Total Health. 1982 Sept:47-9. Available
from the A. Keith Brewer International Science Library
at (608) 647-6513.
-
Nieper HA. Regimen
for the treatment of multiple sclerosis (unpublished ms.,
updated 1994). Available as article #MS10 from the A. Keith
Brewer International Science Library at (608) 647-6513
or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Nieper HA. The
treatment of multiple sclerosis (unpublished ms., 1985).
Available as article #MS12 from the A. Keith Brewer International
Science Library at (608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Strause LG, Hegenauer
J, Saltman P, Cone R, Resnick D. Effects of long-term dietary
manganese and copper deficiency on rat skeleton. J Nutr.
1986;116(1):135-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
McCoy H, Kenney
MA, Montgomery C, Irwin A, Williams L, Orrell R. Relation
of boron to the composition and mechanical properties of
bone. Environ Health Perspect. 1994;102(Suppl 7):49-53.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract